In a cancer patient receiving chemotherapy, radiation therapy, or undergoing surgery, can lactated Ringer’s (LR) solution be used for routine intravenous hydration, and what dosing regimen and precautions should be considered?

Lactated Ringer's Solution for Cancer Patients

Primary Recommendation

Lactated Ringer's (LR) solution can be safely used for routine intravenous hydration in cancer patients receiving chemotherapy, radiation therapy, or undergoing surgery, and should be preferred over normal saline in most clinical scenarios to avoid hyperchloremic acidosis and potential renal complications. 1

---

Evidence-Based Fluid Selection Algorithm

Step 1: Screen for Absolute Contraindications

Exclude LR if any of the following are present:

• Severe traumatic brain injury or closed head injury – LR is hypotonic (osmolarity ≈273–277 mOsm/L vs. plasma ≈275–295 mOsm/L) and can worsen cerebral edema; use 0.9% saline instead 2, 1, 3
• Active rhabdomyolysis or crush syndrome – The 4 mmol/L potassium content poses additional risk in these specific conditions 3
• Anaphylaxis requiring fluid resuscitation – Normal saline is preferred as LR might potentially contribute to metabolic acidosis 1, 4

Step 2: Confirm LR is Appropriate for Cancer Patients

LR is explicitly safe and recommended for:

• Perioperative fluid management in cancer surgery, including major abdominal procedures like colorectal resections 2, 1, 5
• Chemotherapy-related hydration, including cisplatin-based regimens that require aggressive pre- and post-hydration 2
• General medical oncology patients requiring IV fluids, as demonstrated in a trial of 360 septic cancer patients showing no difference in mortality between LR and saline 2

---

Dosing and Administration Guidelines

Perioperative Setting

• Intraoperative fluid replacement: Administer LR at rates sufficient to maintain normovolemia, typically 1–2 L during major cancer surgery 5
• Enhanced Recovery After Surgery (ERAS) protocols: Target zero to mildly positive fluid balance in the first 24 hours post-surgery 2
• Avoid excessive positive fluid balance, particularly after lung resection surgery in thoracic oncology patients 2

Chemotherapy Hydration (Cisplatin Example)

• Pre-cisplatin hydration: Administer adequate IV fluids (typically 1–2 L LR) before each cycle to prevent renal toxicity 2
• Post-cisplatin hydration: Continue IV fluids for 5–7 days in the outpatient setting if needed to prevent or treat dehydration 2
• Monitor closely for myelosuppression, electrolyte loss, and end-organ toxicities after each cycle 2

Intraperitoneal (IP) Chemotherapy

• For ovarian cancer patients receiving IP cisplatin: Give generous IV hydration with LR before and after each IP dose to prevent renal toxicity, nausea, vomiting, and metabolic complications 2

---

Clinical Advantages of LR Over Normal Saline

Metabolic Benefits

• Prevents hyperchloremic metabolic acidosis that occurs with large-volume normal saline administration 1, 6
• Maintains better acid-base balance with more stable bicarbonate levels 1
• Reduces risk of acute kidney injury by 1.1% absolute risk reduction compared to saline 1

Electrolyte Considerations

• The 4 mmol/L potassium content is physiologic and does not cause hyperkalemia, even in renal transplant recipients 1, 6
• In fact, renal transplant patients receiving saline developed higher potassium levels than those receiving LR, likely due to saline-induced acidosis promoting transcellular potassium shifts 1, 6
• The lactate in LR causes only modest, clinically insignificant increases in serum lactate that do not interfere with lactate monitoring 1, 7

Renal Protection

• Large randomized trials (≈30,000 patients) showed comparable plasma potassium between LR and saline groups, with no increased hyperkalemia risk 1
• LR is safe in patients with mild-to-moderate hyperkalemia (K⁺ 5.0–6.5 mmol/L) or chronic kidney disease 3

---

Important Clinical Caveats

Common Pitfalls to Avoid

1. Do not withhold LR due to unfounded potassium concerns – The 4 mmol/L concentration cannot create hyperkalemia in patients with normal or even mildly elevated potassium 1, 3

2. Do not use hypotonic solutions (e.g., D5 0.45% saline) for maintenance fluids, as they significantly increase hyponatremia risk 4

3. Limit normal saline to 1–1.5 L maximum when used, then switch to balanced crystalloids to avoid chloride overload 1, 3

4. Monitor for fluid overload in patients with compromised cardiac or renal function, adjusting rates accordingly 2

Special Populations

• Patients with liver disease: LR remains appropriate, though benefits may be slightly reduced as the liver metabolizes lactate to bicarbonate 1
• Neurosurgical oncology patients: If brain metastases or increased intracranial pressure are present, use 0.9% saline instead of LR 2, 3

---

Comparative Trial Evidence

High-Quality Studies Show Equivalence or Superiority

• SOLAR trial (2020): 8,616 surgical patients showed no clinically meaningful difference in major complications between LR and saline (5.8% vs. 6.1%), with absolute differences <0.5% 5
• FLUID trial (2025): 43,626 patients in a hospital-wide crossover trial showed no significant difference in 90-day death or readmission (20.3% LR vs. 21.4% saline) 8
• Renal transplant trial (2005): LR was associated with significantly less hyperkalemia (0% vs. 19%, P=0.05) and metabolic acidosis (0% vs. 31%, P=0.004) compared to saline 6
• Cancer-specific evidence: A trial of 360 septic cancer patients found no mortality difference between LR and saline 2

---

Practical Implementation Summary

For routine cancer patient hydration:

1. Default to LR for all IV fluid needs unless contraindications exist 1
2. Screen for severe TBI, rhabdomyolysis, or anaphylaxis – use saline if present 1, 3
3. Administer adequate volumes for chemotherapy protocols (1–2 L pre/post-cisplatin) 2
4. Target normovolemia in perioperative settings, avoiding excessive positive balance 2
5. Monitor electrolytes, renal function, and acid-base status regularly 2, 1